Communication

Gene Expression of Pregnancy Neutrophils Differs for Protease versus Lipopolysaccharide Stimulation

Scott W. Walsh *, Marwah Al Dulaimi and Jerome F. Strauss III

Department of Obstetrics and Gynecology, Virginia Commonwealth University, Richmond, VA 23298-0034, USA; marwah.aldulaimi@vcuhealth.org (M.A.D.); jerome.strauss@pennmedicine.upenn.edu (J.F.S.III)
* Correspondence: scott.walsh@vcuhealth.org

Abstract: Neutrophils, which extensively infiltrate maternal systemic blood vessels in preeclampsia, express protease-activated receptor 1 (PAR-1) but only during pregnancy. Neutrophils are generally considered to be non-specific in their response, but the pregnancy-specific expression of PAR-1 could result in a gene expression profile unique to pregnancy, which could help explain why the maternal inflammatory response in preeclampsia is systemic rather than localized. We sought to determine if gene expression of pregnancy neutrophils would differ if stimulated by a protease versus bacterial lipopolysaccharide (LPS). We isolated neutrophils from normal pregnant women at 30 weeks’ gestation and cultured them with elastase or LPS. We used elastase because it is a protease elevated in women with preeclampsia, and it activates pregnancy neutrophils via PAR-1. RNA was isolated from the neutrophils for sequencing of the transcriptomes. We discovered many differences in the gene expression profiles. For example, exposure to elastase resulted in three times more uniquely expressed genes than LPS, and the number of significantly differentially upregulated and downregulated genes was greater for elastase. Analysis of canonical pathways revealed similarities for innate immunity but also differences. LPS treatment enriched more pathways, but elastase activated more genes in each pathway. Elastase treatment enriched the MAPK signaling pathway, whereas LPS did not. This is significant because MAPK is a key mediator of transcriptional responses. These findings indicate that protease stimulation of pregnancy neutrophils results in a different profile than stimulation with LPS, which may help explain why the sterile inflammatory response of preeclampsia is systemic and unique to pregnancy.

Keywords: preeclampsia; pregnancy; neutrophils; gene expression; protease-activated receptor 1; elastase; lipopolysaccharide

1. Introduction

Neutrophils, as part of the innate immune system, are important sentinels to protect the body from wound infections. As such, their response is localized and generally considered to be non-specific. However, in women with preeclampsia, there is extensive systemic infiltration of neutrophils into the mother’s blood vessels [1–3] which initiates a sterile inflammatory response very different from that of a wound infection. This raises the question if this different response is mediated by a difference in gene expression.

Pregnancy neutrophils are unique in that they express protease-activated receptor 1 (PAR-1), which is not expressed in neutrophils of non-pregnant subjects [4,5]. This means pregnancy neutrophils can be activated by a mechanism (proteases) that is specific to pregnancy, which could result in a neutrophil gene expression profile unique to pregnancy. There are at least three proteases elevated in preeclampsia that activate PAR-1, neutrophil elastase, matrix metalloproteinase 1 (MMP-1) and thrombin [6–12]. We have previously shown that elastase and MMP-1 activate nuclear factor-kappa B (NF-kB) in pregnancy neutrophils via PAR-1 to stimulate inflammatory response [6].
In this study, we sought to determine if the gene expression profile of pregnancy neutrophils differs if stimulated by a protease that activates PAR-1 versus lipopolysaccharide (LPS), a bacterial product that activates the innate immune system.

2. Results

Figure 1 shows the co-expression Venn diagram for the number of genes that are uniquely expressed for each treatment group, with the overlapping regions showing the number of genes that are co-expressed between each group for pregnancy neutrophils treated with elastase or LPS. Elastase resulted in three times more uniquely expressed genes than LPS. A total of 299 were uniquely expressed with elastase as compared to 96 for LPS.

Figure 1. Co-expression Venn diagram. Pregnancy neutrophils were obtained at approximately 30 weeks’ gestation and treated with elastase or lipopolysaccharide (LPS). Elastase treatment resulted in 3 times more uniquely expressed genes than LPS. A total of 299 were uniquely expressed with elastase as compared to 96 for LPS.

Figure 2 shows a heatmap for the cluster analysis of genes with high (red) expression levels and genes with low (green) expression levels. The elastase treatment group was almost a mirror image of untreated neutrophils: Genes with low expression in the control group were highly expressed in neutrophils treated with elastase, and those with high expression in the control group showed low expression in the elastase-treated neutrophils. Pregnancy neutrophils treated with LPS were clearly different from both control neutrophils and those exposed to elastase.

Figure 3 shows the number of significantly differentially regulated genes that were either upregulated or downregulated by treatments. Overall, treatment with elastase resulted in more upregulated and more downregulated genes than treatment with LPS. Elastase caused 344 more genes to be upregulated than LPS as compared to the control group, and 430 more to be downregulated. When elastase was compared to LPS, elastase caused 221 more genes to be downregulated and 66 more to be upregulated. Figure 4 presents the volcano plot for LPS versus elastase treatment for significantly differentially expressed genes.
Figure 2. Cluster analysis heatmap of differentially expressed genes with high (red) expression levels and genes with low (green) expression levels. Cluster analysis of high and low expressed genes revealed significant differences. Elastase and LPS were clearly different from control, but they were also clearly different from each other.

The Gene Ontology Enrichment Analysis for significantly upregulated molecular function pathways is presented in Table 1. The most significantly upregulated pathways (cytokine receptor binding, cytokine activity, chemokine activity, chemokine receptor binding) were similar for elastase and LPS treatment in order of significance and number of genes involved in each pathway. However, after the first four pathways, the order of significance, number of genes, and number of pathways was different. In total, 11 pathways were upregulated by elastase treatment and 17 by LPS. There were no significantly downregulated pathways.
Figure 3. Number of significantly differentially regulated genes (DEG) either upregulated or downregulated by treatments. Elastase upregulated approximately 30% more genes than LPS and downregulated approximately 75% more genes than LPS. Overall, elastase differently regulated more genes than LPS.

Figure 4. Volcano plot for significantly differentially regulated genes comparing elastase with LPS. Elastase upregulated 66 more genes than LPS and downregulated 221 more genes than LPS.
Table 1. Gene Ontogeny Molecular Function Enrichment Pathways.

| Pathway Description                                      | Number of Genes | padj       |
|----------------------------------------------------------|-----------------|------------|
| **Elastase vs. Control**                                 |                 |            |
| cytokine receptor binding                                | 40              | 4.44 × 10⁻⁸|
| cytokine activity                                        | 34              | 4.44 × 10⁻⁸|
| chemokine activity                                       | 12              | 0.00023355 |
| chemokine receptor binding                               | 13              | 0.0004327  |
| MAP kinase phosphatase activity                          | 7               | 0.0004775  |
| receptor regulator activity                               | 42              | 0.00200428 |
| receptor ligand activity                                 | 40              | 0.00200428 |
| MAP kinase tyrosine-serine/threonine phosphatase activity| 6               | 0.00266583 |
| CCR chemokine receptor binding                           | 8               | 0.00933415 |
| growth factor receptor binding                           | 17              | 0.01480743 |
| growth factor activity                                   | 17              | 0.04707246 |
| **LPS vs. Control**                                      |                 |            |
| cytokine receptor binding                                | 39              | 5.63 × 10⁻¹⁰|
| cytokine activity                                        | 31              | 2.43 × 10⁻⁸|
| chemokine activity                                       | 12              | 1.62 × 10⁻⁵|
| chemokine receptor binding                               | 13              | 3.10 × 10⁻⁵|
| CCR chemokine receptor binding                           | 9               | 0.00031289 |
| receptor ligand activity                                 | 37              | 0.00031289 |
| receptor regulator activity                               | 37              | 0.00131844 |
| MAP kinase tyrosine-serine/threonine phosphatase activity| 5               | 0.01543015 |
| 14-3-3 protein binding                                   | 7               | 0.01543015 |
| G-protein coupled receptor binding                       | 23              | 0.01698056 |
| MAP kinase phosphatase activity                          | 5               | 0.01795535 |
| RNA polymerase II proximal promoter sequence-specific DNA binding | 33            | 0.02366222 |
| growth factor receptor binding                           | 14              | 0.03717801 |
| proximal promoter sequence-specific DNA binding           | 33              | 0.03773685 |
| RNA polymerase II distal enhancer sequence-specific DNA binding | 10           | 0.04702544 |
| lipoprotein particle binding                              | 6               | 0.04702544 |
| protein–lipid complex binding                            | 6               | 0.04702544 |

The adjusted p-value (padj), which is the transformation of the p-value after accounting for multiple testing, was used to determine statistical significance for these pathways. The padj values were calculated by Novogene.

Table 2 shows the KEGG (Kyoto Encyclopedia of Genes and Genomes) Enrichment Analysis, which identifies significantly enriched metabolic and signal transduction pathways associated with differentially expressed genes related to biological functions. KEGG pathways related to disease information are not shown because they did not pertain to preeclampsia. The most significantly upregulated pathways, TNF signaling and IL-17 signaling, were similar for elastase and LPS treatment, although the number of genes for each pathway was greater for elastase. Thereafter, the pathways differed in order of significance, the number of genes and the number of pathways. Elastase upregulated 17 metabolic pathways and LPS upregulated 21. Of significance, elastase
upregulated the MAPK signaling pathway but LPS did not. There were no significantly downregulated pathways.

### Table 2. KEGG Metabolic Enrichment Pathways.

| Pathway Description | Number of Genes | padj          |
|---------------------|-----------------|--------------|
| **Elastase vs. Control** |                  |              |
| TNF signaling pathway | 34              | \(1.32 \times 10^{-13}\) |
| IL-17 signaling pathway | 27             | \(1.03 \times 10^{-10}\) |
| NOD-like receptor signaling pathway | 37          | \(1.03 \times 10^{-10}\) |
| C-type lectin receptor signaling pathway | 24        | \(6.11 \times 10^{-7}\) |
| NF-kappa B signaling pathway | 21          | \(4.46 \times 10^{-6}\) |
| Cytokine-cytokine receptor interaction | 35         | \(8.26 \times 10^{-5}\) |
| Toll-like receptor signaling pathway | 17         | \(0.000551\) |
| RIG-I-like receptor signaling pathway | 13        | \(0.00103201\) |
| Chemokine signaling pathway | 25          | \(6.38 \times 10^{-5}\) |
| Cytosolic DNA-sensing pathway | 21        | \(0.00221418\) |
| AGE-RAGE signaling pathway in diabetic complications | 16        | \(0.00281374\) |
| Necroptosis | 21          | \(0.00440828\) |
| Neurotrophin signaling pathway | 17        | \(0.0127872\) |
| JAK-STAT signaling pathway | 19          | \(0.0142866\) |
| Th17 cell differentiation | 14          | \(0.01622074\) |
| MAPK signaling pathway | 20          | \(0.02969086\) |
| Th1 and Th2 cell differentiation | 12        | \(0.03381456\) |

| Pathway Description | Number of Genes | padj          |
|---------------------|-----------------|--------------|
| **LPS vs. Control** |                  |              |
| TNF signaling pathway | 27              | \(1.14 \times 10^{-9}\) |
| IL-17 signaling pathway | 23            | \(1.01 \times 10^{-8}\) |
| NF-kappa B signaling pathway | 22          | \(9.69 \times 10^{-8}\) |
| C-type lectin receptor signaling pathway | 22        | \(6.87 \times 10^{-7}\) |
| NOD-like receptor signaling pathway | 27        | \(1.98 \times 10^{-6}\) |
| Cytokine-cytokine receptor interaction | 31         | \(6.38 \times 10^{-5}\) |
| RIG-I-like receptor signaling pathway | 13        | \(0.00018154\) |
| Toll-like receptor signaling pathway | 16        | \(0.0002092\) |
| Chemokine signaling pathway | 23        | \(0.00065273\) |
| AGE-RAGE signaling pathway in diabetic complications | 14        | \(0.00820716\) |
| Cytosolic DNA-sensing pathway | 9          | \(0.00845507\) |
| JAK-STAT signaling pathway | 17          | \(0.01259687\) |
| Th17 cell differentiation | 13          | \(0.01280896\) |
| B cell receptor signaling pathway | 11        | \(0.01290435\) |
| Necroptosis | 17          | \(0.01834355\) |
| Adipocytokine signaling pathway | 10         | \(0.0190038\) |
| T cell receptor signaling pathway | 13         | \(0.0190038\) |
| Neurotrophin signaling pathway | 14        | \(0.02891941\) |
| Th1 and Th2 cell differentiation | 11        | \(0.03029502\) |
| Ferroptosis | 7           | \(0.03301585\) |
| Apoptosis | 15          | \(0.03522501\) |

The adjusted p-value (padj), which is the transformation of the p-value after accounting for multiple testing, was used to determine statistical significance for these pathways. The padj values were calculated by Novogene.
3. Discussion

In this study, we show that the gene expression profile of pregnancy neutrophils differs depending on whether they are stimulated by a protease versus LPS. Different gene expression profiles may help explain why the pregnancy inflammatory response in preeclampsia is so different from the innate inflammatory response to localized infection. With a wound, the inflammatory response is usually restricted to the site of injury, and neutrophils infiltrate in response to bacterial or other microbial infection. In preeclampsia, the neutrophil inflammatory response is systemic, affecting the mother’s entire circulation. In a wound, neutrophils infiltrate deep into the tissue killing, trapping, and phagocytosing bacteria. In preeclampsia, neutrophils primarily adhere and flatten onto the endothelium and only infiltrate as deep as the vascular smooth muscle [1–3]. In a wound, neutrophil infiltration is followed by monocyte infiltration, and the subsequent differentiation of monocytes into macrophages, which assist neutrophils in cleaning up the infection site and start recruiting fibroblasts to heal the wound. In preeclampsia, vascular infiltration is limited to neutrophils; monocytes and lymphocytes do not infiltrate the mother’s blood vessels [13]. This selective neutrophil infiltration appears to be regulated by interleukin-17 (IL-17), which is increased in the mother’s circulation before clinical symptoms appear and selectively stimulates vascular expression of neutrophil chemokines as opposed to monocyte chemokines [14]. Systemic neutrophil activation and production of superoxide in preeclamptic women has been likened to sepsis [15], but the inflammation of preeclampsia is very different. Sepsis involves systemic infection, whereas preeclampsia is a sterile systemic inflammatory response.

It is evident that the neutrophil inflammatory response in preeclampsia is very different from the action of neutrophils to protect the body from infection. In this study, we found many differences in gene expression induced by elastase versus LPS. Venn diagram analysis revealed almost 300 uniquely expressed genes when pregnancy neutrophils were stimulated with elastase, whereas LPS resulted in less than 100. Heatmap cluster analysis for genes with high expression and low expression revealed very different patterns for elastase and LPS. The number of differentially regulated genes (DEG) were also different for these two activators. Elastase upregulated approximately 30% more genes than LPS and downregulated approximately 75% more than LPS. Overall, elastase differently regulated more genes than LPS.

When canonical pathways for Gene Ontology Enrichment Analysis for molecular function and KEGG Enrichment Analysis for metabolic pathways and transcription factors were analyzed, both differences and similarities were evident. The most significantly up-regulated pathways were the same for both elastase and LPS. For molecular function, the first four pathways, cytokine receptor binding, cytokine activity, chemokine activity and chemokine receptor binding, were significantly enriched for both. For KEGG analysis, the first two pathways, TNF signaling and IL-17 signaling, were the same. It is not surprising that pathways related to innate immunity would be the same, since neutrophils are activated by both elastase and LPS. However, after this, the molecular function and metabolic pathway enrichments differed in terms of the order of significance, the number of genes involved and even different pathways and the number of pathways enriched.

Clearly, protease activation and bacterial LPS activation produce different gene profiles, but how this occurs is not known. Certain epigenetic mechanisms such as DNA methylation are not likely to be involved because the genomic DNA of circulating neutrophils is de-methylated [16]. Thus, differences in gene expression are more likely regulated by differences in signal transduction pathways and the regulation of transcription factor activity. This notion is supported by differences in the pathways enriched for KEGG metabolic and signal transduction. The number of pathways, the pathways enriched, and number of genes in the pathway differed for elastase and LPS. LPS enriched more pathways than elastase, but for pathways enriched by both, elastase consistently activated more genes. LPS enriched five pathways not enriched by elastase, but of note, elastase significantly enriched the MAPK signaling pathway, whereas LPS did not. This is an important difference because
MAPK is a key mediator of transcriptional responses and controls gene expression in a number of ways, including phosphorylation and the regulation of transcription factors [17]. MAPK is involved in many metabolic and signal transduction pathways, so this kinase could account for differences in gene expression profiles. Our findings show that pregnancy neutrophils can express different gene profiles depending on the stimulus. The ability of neutrophils to express distinct transcriptional differences has also been shown to apply to neutrophils obtained from non-pregnant subjects with different chronic inflammatory states [18].

Circulating neutrophil elastase, MMP-1 and thrombin are all elevated in preeclampsia [6–12]. MMP-1 is significantly elevated 10 weeks before clinical symptoms of preeclampsia appear, a time when the women are thought to have a normal pregnancy. In contrast, neutrophil elastase and thrombin are not elevated until after the manifestation of symptoms. This suggests that MMP-1 may be responsible for the initial activation of neutrophils, but once started, neutrophil activation becomes a feed forward process accelerated by MMP-1, neutrophil elastase and thrombin. This is consistent with the progressive worsening of clinical symptoms in preeclamptic women.

Neutrophils constitutively express PAR-2 in both pregnant and non-pregnant individuals [4]. However, PAR-2 does not appear to play an important role in pregnancy based on the observation that targeted inhibition of PAR-1 alone is sufficient to prevent protease activation of NF-κB and expression of inflammatory genes in pregnancy neutrophils [6].

The control of neutrophil gene expression in preeclampsia is far more complex than shown in this study comparing elastase with LPS. In preeclampsia, multiple factors are potentially involved. Lipid peroxides, which are secreted by the placenta [19,20], are potent activators of neutrophils [21–23]. Lipid peroxides induce expression of cyclooxygenase (COX-2) [24] and stimulate neutrophil production of superoxide, tumor necrosis factor-alpha (TNFα) and thromboxane [22,23]. Maternal circulating levels of TNFα are increased [25–27] and activate neutrophils [28–30]. Hematopoietic cytokines, granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF), which activate and promote the expansion of neutrophil lineages, are elevated in preeclampsia [31,32]. Chemokines, such as interleukin-8 (IL-8) produced by neutrophils and expressed in vascular smooth muscle cells under the influence of IL-17 [14], are additional activators [30,33–36]. Moreover, damage-associated molecular patterns (e.g., high-mobility group box-1 protein (HMGB1) and the extra domain A of fibronecin (EDA)) released from tissues damaged in the response to preeclampsia can also activate neutrophils [37–39]. Each of these factors activate neutrophils by different receptors and thus may have their own unique impact on the expression of genes, the combination of which results in the overall transcriptome profile of neutrophils in preeclampsia [16].

4. Materials and Methods

4.1. Study Subjects

Gestational age matched blood samples were collected at 30 weeks’ gestation from a multi-racial/ethnic population of women with normal pregnancy who went on to deliver at term (n = 9). The Office of Research Subjects Protection of Virginia Commonwealth University approved this study (HM20009145). All subjects gave informed consent, and the procedures followed were in accordance with institutional guidelines. Clinical characteristics of the patients are given in Table 3.
Table 3. Clinical Characteristics of Patients.

| Variable                                | Normal Pregnant |  
|-----------------------------------------|-----------------|
|                                        | n = 9           |
| Maternal age (years)                    | 29.8 ± 4.4      |
| Pre-pregnancy BMI (kg/m²)               | 29.5 ± 11.3     |
| BMI at sample collection (kg/m²)        | 34.5 ± 11.4     |
| Systolic blood pressure at 30 Weeks (mmHg) | 109 ± 13        |
| Diastolic blood pressure at 30 Weeks (mmHg) | 68 ± 11         |
| Primiparous                             | 1               |
| Multiparous                             | 8               |
| Race                                     |                 |
| White                                    | 4               |
| Black                                    | 3               |
| Hispanic                                 | 1               |
| Asian                                    | 1               |
| Type of Delivery                         |                 |
| C-section                                | 2               |
| Vaginal                                  | 7               |
| Gestational age at sample collection (weeks) | 29.6 ± 2.6     |
| Gestational age at delivery (weeks)      | 38.7 ± 2.4      |
| Infant birth weight (grams)              | 3288 ± 322      |

Values are mean ± SD.

4.2. Neutrophil Cell Culture and RNA Sequencing

First, 2-10 mL heparin tubes of blood were collected. Lymphocytes and monocytes were separated from granulocytes (96% of which are neutrophils) by Histopaque (1077/1119) density gradient centrifugation according to the manufacturer’s protocol (Sigma Aldrich, St. Louis, MO, USA) and as previously described [2,23,40]. Neutrophils were seeded at an average of 5,000,000 cells per mL in Falcon 4-well cell culture slides (#354104) and cultured in Iscove’s Modified Dulbecco’s Medium supplemented with 10% fetal bovine serum and 1% antibiotics and antmycotics (100 U/mL penicillin, 100 µg/mL streptomycin, 0.25 µg/mL amphotericin B) at 37 °C in a humidified 5% CO₂ atmosphere. Neutrophils were incubated with the following treatments for 2 h: (1) control media; (2) elastase (0.33 U/mL, Sigma Aldrich); (3) LPS (200 ng/mL, Sigma Aldrich). We used elastase because it is a neutrophil product that is elevated in women with preeclampsia, and we previously showed that it activates NF-κB in pregnancy neutrophils via PAR-1 [6]. We used LPS because it is a bacterial product that activates neutrophils through a different mechanism, that is, via toll-like receptors. RNA was isolated from neutrophils using TRIzol Reagent (ThermoFisher Scientific, Wilmington, DE) according to the manufacturer’s protocol. RNA concentrations were measured, and their quality assessed using a NanoDrop 2000 spectrophotometer (ThermoFisher Scientific). Total RNA (0.5 µg/20 µL) was sent to Novogene Corporation, Inc. (Sacramento, CA) for Human mRNA Sequencing. RNA sample quality was determined by Novogene before proceeding with mRNA library preparation (poly A enrichment). A paired-end 150 bp sequencing strategy was used to sequence the samples using Illumina NovaSeq 6000 Sequencing Platform. The resulting data were checked for quality before bioinformatic analyses. The hg38 genome was used as the reference genome for gene alignment. Novogene provided the bioinformatics analysis for the RNA-seq Quantification Analysis Report along with publication-ready results.
5. Conclusions

In this study, we demonstrated that the gene expression profile of pregnancy neutrophils differs when stimulated by a protease elevated in preeclampsia versus stimulated by LPS, a bacterial product that activates the innate immune system. The pregnancy-specific expression of PAR-1, which allows neutrophils to respond to activators (proteases) that they otherwise would not recognize, may explain why the inflammatory response in preeclampsia is systemic and has unique features.

Author Contributions: S.W.W., conceptualization, writing—original draft preparation, data curation; M.A.D., methodology, performed experiments; J.F.S.III, writing—review and editing. All authors have read and agreed to the published version of the manuscript.

Funding: This work was funded by Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) grant 5R01 HD088386 (SWW).

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Office of Research Subjects Protection of Virginia Commonwealth University (HM20009145, approved 6/10/2021).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Complete tabular data presented in this study for gene ontogeny pathways and gene expression are available on request from the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Leik, C.E.; Walsh, S.W. Neutrophils Infiltrate Resistance-Sized Vessels of Subcutaneous Fat in Women with Preeclampsia. *Hypertension* 2004, 44, 72–77. [CrossRef] [PubMed]
2. Mishra, N.; Nugent, W.H.; Mahavadi, S.; Walsh, S.W. Mechanisms of Enhanced Vascular Reactivity in Preeclampsia. *Hypertension* 2011, 58, 867–873. [CrossRef] [PubMed]
3. Shah, T.J.; Walsh, S.W. Activation of NF-κB and expression of COX-2 in association with neutrophil infiltration in systemic vascular tissue of women with preeclampsia. *Am. J. Obstet. Gynecol.* 2007, 196, 48.e1–48.e8. [CrossRef] [PubMed]
4. Wang, Y.; Gu, Y.; Lucas, M.J. Expression of thrombin receptors in endothelial cells and neutrophils from normal and preeclamptic pregnancies. *J. Clin. Endocrinol. Metab.* 2002, 87, 3728–3734. [CrossRef]
5. Shpacovitch, V.; Feld, M.; Hollenberg, M.D.; Luger, T.A.; Steinhoff, M. Role of protease-activated receptors in inflammatory responses, innate and adaptive immunity. *J. Leukoc. Biol.* 2008, 83, 1309–1322. [CrossRef]
6. Walsh, S.W.; Nugent, W.H.; Al Dulaimi, M.; Washington, S.L.; Dacha, P.; Strauss, J.F., 3rd. Proteases Activate Pregnancy Neutrophils by a Protease-Activated Receptor 1 Pathway: Epigenetic Implications for Preeclampsia. *Reprod. Sci.* 2020, 27, 2115–2127. [CrossRef]
7. Cadroy, Y.; Grandjean, H.; Pichon, J.; Desprats, R.; Berrebi, A.; Fournié, A.; Boneu, B. Evaluation of six markers of haemostatic system in normal pregnancy and pregnancy complicated by hypertension or pre-eclampsia. *Br. J. Obstet. Gynaecol.* 1993, 100, 416–420. [CrossRef]
8. Chaiworapongsa, T.; Yoshimatsu, J.; Espinoza, J.; Kim, Y.M.; Berman, S.; Edwin, S.; Yoon, B.H.; Romero, R. Evidence of vivogenation of thrombin in patients with small-for-gestational-age fetuses and pre-eclampsia. *J. Matern. Neonatal Med.* 2002, 11, 362–367. [CrossRef]
9. Greer, I.A.; Haddad, N.G.; Dawes, J.; Johnstone, F.D.; Calder, A.A. Neutrophil activation in pregnancy-induced hypertension. *BJOG Int. J. Obstet. Gynaecol.* 1989, 96, 978–982. [CrossRef]
10. Gupta, A.; Gebhardt, S.; Hillermann, R.; Holzgrewe, W.; Hahn, S. Analysis of plasma elastase levels in early and late onset preeclampsia. *Arch. Gynecol. Obstet.* 2005, 273, 239–242. [CrossRef]
11. Schjette, R.; Haugen, G.; Wisloff, F. Markers of intravascular coagulation and fibrinolysis in preeclampsia: Association with intrauterine growth retardation. *Acta Obstet. Gynecol. Scand.* 1997, 76, 541–546. [CrossRef] [PubMed]
12. Van Wijk, M.J.; Boer, K.; Berckmans, R.J.; Meijers, J.C.; van der Post, J.A.; Stark, A.; Van Bavel, E.; Nieuwland, R. Enhanced coagulation activation in preeclampsia: The role of APC resistance, microparticles and other plasma constituents. *Thromb. Haemost.* 2002, 88, 415–420. [CrossRef]
13. Cadden, K.A.; Walsh, S.W. Neutrophils, but Not Lymphocytes or Monocytes, Infiltrate Maternal Systemic Vasculature in Women with Preeclampsia. *Hypertens. Pregnancy* 2008, 27, 396–405. [CrossRef] [PubMed]
14. Walsh, S.W.; Nugent, W.H.; Archer, K.J.; Al Dulaimi, M.; Washington, S.L.; Strauss, J.F. Epigenetic Regulation of Interleukin-17-Related Genes and Their Potential Roles in Neutrophil Vascular Infiltration in Preeclampsia. Reprod. Sci. 2022, 29, 154–162. [CrossRef] [PubMed]

15. Sacks, G.P.; Studena, K.; Sargent, I.L.; Redman, C.W. Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am. J. Obstet. Gynecol. 1998, 179, 80–86. [CrossRef]

16. Walsh, S.W.; Al Dulaimi, M.; Archer, K.J.; Strauss, J.F. Patterns of Maternal Neutrophil Gene Expression at 30 Weeks of Gestation, but Not DNA Methylation, Distinguish Mild from Severe Preeclampsia. Int. J. Mol. Sci. 2021, 22, 12876. [CrossRef]

17. Whitmarsh, A.J. Regulation of gene transcription by mitogen-activated protein kinase signaling pathways. Biochim. Biophys. Acta 2007, 1773, 1285–1298. [CrossRef]

18. Jiang, K.; Sun, X.; Chen, Y.; Shen, Y.; Jarvis, J.N. RNA sequencing from human neutrophils reveals distinct transcriptional differences associated with chronic inflammatory states. BMC Med. Genom. 2015, 8, 55. [CrossRef]

19. Walsh, S.W.; Vaughan, J.E.; Wang, Y.; Roberts, L.J., II. Placental isoprostane is significantly increased in preeclampsia. FASEB J. 2000, 14, 1289–1296. [CrossRef]

20. Walsh, S.W.; Wang, Y. Secretion of lipid peroxides by the human placenta. Am. J. Obstet. Gynecol. 1993, 169, 1462–1466. [CrossRef]

21. Görög, P. Activation of human blood monocytes by oxidized polyunsaturated fatty acids: A possible mechanism for the generation of lipid peroxides in the circulation. Int. J. Exp. Pathol. 1991, 72, 227–237. [PubMed]

22. Vaughan, J.E.; Walsh, S.W. Neutrophils from pregnant women produce thrombomodulin and tumor necrosis factor-α in response to linoleic acid and oxidative stress. Am. J. Obstet. Gynecol. 2005, 193, 830–835. [CrossRef] [PubMed]

23. Vaughan, J.E.; Walsh, S.W.; Ford, G.D. Thrombomodulin mediates neutrophil superoxide production in pregnancy. Am. J. Obstet. Gynecol. 2006, 195, 1415–1420. [CrossRef] [PubMed]

24. Bachawaty, T.; Washington, S.L.; Walsh, S.W. Neutrophil Expression of Cyclooxygenase 2 in Preeclampsia. Reprod. Sci. 2010, 17, 465–470. [CrossRef]

25. Conrad, K.P.; Miles, T.M.; Benyo, D.F. Circulating Levels of Immunoreactive Cytokines in Women with Preeclampsia. Am. J. Reprod. Immunol. 1998, 40, 102–111. [CrossRef]

26. Ferguson, K.K.; Meeker, J.; McLraith, T.F.; Mukherjee, B.; Cantonwine, D.E. Repeated measures of inflammation and oxidative stress biomarkers in preeclamptic and normotensive pregnancies. Am. J. Obstet. Gynecol. 2016, 216, 527.e1–527.e9. [CrossRef]

27. Kupferminc, M.J.; Peaceman, A.M.; Wigton, T.R.; Rehnberg, K.A.; Socol, M.L. Tumor necrosis factor-alpha is elevated in plasma and amniotic fluid of patients with severe preeclampsia. Am. J. Obstet. Gynecol. 1994, 170, 1752–1759. [CrossRef]

28. Ferrante, A. Activation of neutrophils by interleukins-1 and -2 and tumor necrosis factors. Immunol. Ser. 1992, 57, 417–436.

29. Richter, J.; Gullberg, U.; Lantz, M. TNF-induced superoxide anion production in adherent human neutrophils involves both the p55 and p75 TNF receptor. J. Immunol. 1995, 154, 4142–4149. [CrossRef]

30. Smart, S.J.; Casale, T.B. TNF-alpha-induced transendothelial neutrophil migration is IL-8 dependent. Am. J. Physiol. Cell. Mol. Physiol. 1994, 266, L238–L245. [CrossRef]

31. Hayashi, M.; Hamada, Y.; Ohkura, T. Elevation of granulocyte-macrophage colony-stimulating factor in the placenta and blood in preeclampsia. Am. J. Obstet. Gynecol. 2004, 190, 456–461. [CrossRef] [PubMed]

32. Matsubara, K.; Ochi, H.; Kitagawa, H.; Yamanaka, K.; Kusanagi, Y.; Ito, M. Concentrations of Serum Granulocyte-Colony-Stimulating Factor in Normal Pregnancy and Preeclampsia. Hypertens. Pregnancy 1999, 18, 95–106. [CrossRef] [PubMed]

33. Ina, K.; Kusugami, K.; Yamaguchi, T.; Imada, A.; Hosokawa, T.; Ohsuga, M.; Shinoda, M.; Ando, T.; Ito, K.; Yokoyama, Y. Mucosal interleukin-8 is involved in neutrophil migration and binding to extracellular matrix in inflammatory bowel disease. Am. J. Gastroenterol. 1997, 92, 1342–1346. [CrossRef]

34. Mellembakken, J.R.; Aukrust, P.; Hestdal, K.; Ueland, T.; Videm, V. Chemokines and leukocyte activation in the fetal circulation during preeclampsia. Hypertension 2001, 38, 394–398. [CrossRef] [PubMed]

35. Romero, R.; Ceska, M.; Avila, C.; Mazor, M.; Behnke, E.; Lindley, I. Neutrophil attractant/activating peptide-1/interleukin-8 is involved in neutrophil migration and binding to extracellular matrix in inflammatory bowel disease. Am. J. Obstet. Gynecol. 2000, 183, 1381–1391. [CrossRef]

36. Pradervand, P.-A.; Clerc, S.; Frantz, J.; Rotaru, C.; Bardy, D.; Weaber, B.; Liaudet, L.; Vial, Y.; Feihl, F. High mobility group box 1 protein (HMGB-1): A pathogenic role in preeclampsia? Placenta 2014, 35, 784–786. [CrossRef]

37. Park, J.S.; Arcaroli, J.; Yum, H.-K.; Yang, H.; Wang, H.; Yang, K.-Y.; Choe, K.-H.; Strassheim, D.; Pitts, T.M.; Tracey, K.J.; et al. Activation of gene expression in human placenta by high mobility group box 1 protein. Am. J. Physiol. Physiol. 2003, 284, C870–C879. [CrossRef]

38. Estrada-Gutierrez, G.; Cappello, R.E.; Mishra, N.; Romero, R.; Strauss, J.F., 3rd; Walsh, S.W. Increased Expression of Matrix Metalloproteinase-1 in Systemic Vessels of Preeclamptic Women: A Critical Mediator of Vascular Dysfunction. Am. J. Pathol. 2011, 178, 451–460. [CrossRef]